Nuwellis, Inc.
Nuwellis, Inc. is a U.S.-based medical technology company focused on the Aquadex System, an ultrafiltration platform used to remove excess fluid from patients. Its business combines console systems, disposable blood filters and catheters, and related clinical support for hospitals and clinics, with sales centered in the United States and selected international markets.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueCapital equipment used to deliver ultrafiltration therapy in hospital settings.
Single-use blood filters and catheters used with Aquadex consoles.
Training, implementation, and clinical support provided to hospital customers.
Sales outside the U.S. through specialty distributors in selected markets.
Other device-related sales and commercial activity tied to the Aquadex platform.
Customers
Nuwellis sells primarily to hospitals, health systems, and academic medical centers that treat fluid overload in complex patients. Its core users include cardiac surgery, heart failure, critical care, and pediatric programs that need controlled fluid removal and clinical support around therapy delivery.
Buy Aquadex consoles, disposables, and support for inpatient fluid management programs.
Use the system in advanced heart failure and critical care protocols where clinical evidence matters.
Use ultrafiltration around post-cardiac surgery fluid management and recovery.
Adopt the pediatric-cleared system for children needing kidney replacement or fluid therapy.
Purchase products for resale to hospitals and clinics in their local markets.
Strategy
Nuwellis is prioritizing commercial investment in U.S. cardiac surgery, pediatric, and hospital-based outpatient opportunities where it sees the strongest clinical demand. It is also extending the Aquadex platform through software upgrades and product enhancements, while evaluating adjacent renal-monitoring technologies that could broaden its care platform.
The company believes U.S. demand offers the strongest near-term commercial opportunity and supportability.
These clinical settings can increase utilization of the Aquadex platform and deepen hospital relationships.
Device enhancements can support customer satisfaction, retention, and broader clinical use.
Adjacent monitoring technologies could extend the company’s role in cardiorenal care.
Geography
Nuwellis is centered in the United States, where it sells through a direct salesforce and has ten sales territories. It also serves selected foreign jurisdictions through independent specialty distributors, but the company has stated that its focus is the U.S. market and a small set of retained international markets.
Risks
Nuwellis depends on a concentrated customer base, third-party manufacturing, and continued access to capital, so disruptions in any of these areas could materially affect operations. As a medical device company, it also faces regulatory, clinical adoption, reimbursement, and product-performance risks that can slow commercialization or limit utilization.
- Capital funding riskImpact: CriticalLikelihood: High
The company expects to need additional capital to support operations and strategic initiatives.
Exposure: Operating runway and growth investment
- Nasdaq listing complianceImpact: HighLikelihood: High
The stock has faced minimum stockholders' equity and bid-price compliance pressure.
Exposure: Potential delisting and trading restrictions
- Customer concentrationImpact: HighLikelihood: Medium
A limited number of customers account for a large share of revenue, so loss or reduced ordering can materially hurt sales.
Exposure: Largest customer represented 13.7% of annual revenue
- Third-party manufacturing and supply chainImpact: HighLikelihood: Medium
The company depends on external manufacturers and suppliers for commercial volumes and components.
Exposure - Clinical adoption and reimbursementImpact: MediumLikelihood: Medium
Hospitals must adopt ultrafiltration therapy and justify use versus competing treatments.
Exposure
Accounting
Judgemental itemsSales of consoles, disposables, and services are recognized when control transfers, which can shift revenue between periods.
Impact: Quarterly comparability
Freestanding warrants may be classified as liabilities and remeasured at fair value.
Impact: Non-cash earnings volatility
The company must assess whether equipment and other assets remain recoverable.
Impact: Potential write-downs
Equity awards require valuation assumptions that affect operating expenses.
Impact: Reported SG&A and R&D
Tax positions and reserves depend on estimates and can change with new information.
Impact: Net income and balance sheet
Similar listed companies
Publicly listed companies with a comparable business focus.
Nuvectis Pharma, Inc.
NVCT · Pharmaceutical Preparations
Nu-Med Plus, Inc.
NUMD · Surgical & Medical Instruments & Apparatus
Nephros, Inc
NEPH · Surgical & Medical Instruments & Apparatus
Nuvalent, Inc.
Pharmaceutical Preparations
Adagio Medical Holdings, Inc.
ADGM · Surgical & Medical Instruments & Apparatus
Teleflex Incorporated
TFX · Surgical & Medical Instruments & Apparatus
Last updated: 24/09/2026